Back to Search Start Over

Crosstalk between heat shock factor 1 and signal transducer and activator of transcription 3 mediated by interleukin‐8 autocrine signaling maintains the cancer stem cell phenotype in liver cancer.

Authors :
Yang, Zhengyan
Wan, Wenjuan
Zhang, Pai
Wang, Shuangfeng
Zhao, Zhi
Xue, Jingrui
Yao, Mengzhuo
Zhao, Yiwei
Zheng, Weifeng
Niu, Baohua
Wang, Mingli
Li, Hui
Guo, Weikai
Ren, Zhiguang
Hu, Yanzhong
Source :
Journal of Gastroenterology & Hepatology. Jan2023, Vol. 38 Issue 1, p138-152. 15p.
Publication Year :
2023

Abstract

Background and Aim: Liver cancer stem cells (LCSCs) cause therapeutic refractoriness and relapse in hepatocellular carcinoma. Heat shock factor 1 (HSF1) plays versatile roles in multiple cancers. However, the role of HSF1 in LCSCs is not well understood. This study investigated the function and signal mechanisms of HSF1 in maintaining LCSC phenotypes. Methods: We established two LCSC lines, HepG2‐R and HuH‐7‐R. Constitutive activation of HSF1 was observed in these LCSCs. Specific short hairpin RNAs (shRNAs) and chemical inhibitors were used to identify the relationship between HSF1 expression and LCSCs phenotypes. Results: We revealed a concomitant activation modality involving HSF1 and STAT3 in LCSCs and liver cancer tissues. We also found that liver cancer patients whose HSF1 and STAT3 mRNA expression levels were high presented with unfavorable clinicopathological characteristics. Moreover, the secretion of interleukin‐8 (IL‐8) was elevated in the LCSC medium and was directly regulated by HSF1 at the transcriptional level. In turn, IL‐8 activated HSF1 and STAT3 signaling, and a neutralizing IL‐8 antibody inhibited HSF1 and STAT3 activity, reduced cancer stem cell marker expression, and decreased LCSC microsphere formation. Simultaneous intervention with HSF1 and STAT3 led to synergistically suppressed stemness acquisition and growth suppression in the LCSCs in vivo and in vitro. Conclusions: Our study indicates that IL‐8 mediates the crosstalk between the HSF1 and Stat3 signaling pathways in LCSCs and that the combined targeting of HSF1 and STAT3 is a promising treatment strategy for patients with advanced liver cancer. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
08159319
Volume :
38
Issue :
1
Database :
Academic Search Index
Journal :
Journal of Gastroenterology & Hepatology
Publication Type :
Academic Journal
Accession number :
161312075
Full Text :
https://doi.org/10.1111/jgh.16040